New drug BT-062

In a collaborative research effort AERES Biomedical, Ltd. and Biotest AG successfully completed the engineering of the monoclonal antibody BT-062.
The candidate is directed against a tumor-specific target expressed by multiple myeloma.

After BT-062 had shown impressive efficacy in an animal model of the disease, this is an important step towards the clinical development of the candidate.